Zinecard offers cardioprotection

October 20, 2010

Children undergoing anthracycline therapy for acute lymphoblastic leukemia saw cardioprotective benefits with dexrazoxane (Zinecard or Cardioxane), which signifi cantly reduced the occurrence of long-term heart damage without negatively aff ecting the eff ectiveness of chemotherapy.

Children undergoing anthracycline therapy for acute lymphoblastic leukemia saw cardioprotective benefits with dexrazoxane (Zinecard or Cardioxane), which signifi cantly reduced the occurrence of long-term heart damage without negatively aff ecting the eff ectiveness of chemotherapy.

The 205 subjects received either 10 doses of high-dose doxorubicin (300 mg/m2) alone or doxorubicin preceded by an infusion of dexrazoxane.

Sixty-six children who received doxorubicin alone and 68 children who received doxorubicin and dexrazoxane had at least one echocardiogram after treatment.

After fi ve years of follow-up, the mean left ventricular fractional shortening and end-systolic dimension Z-scores were significantly worse than normal for children who received doxorubicin alone, but not for those who also received dexrazoxane (Lancet Oncol online, September 15, 2010).